Connect with us

Health

Alzheimer’s-related dementia could be prevented by experimental drug, researchers say

Published

on

Alzheimer’s-related dementia could be prevented by experimental drug, researchers say

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

That’s according to a new study from Washington University School of Medicine in St. Louis, where researchers ran a clinical trial of people with rare genetic mutations that almost “guarantee” future Alzheimer’s development, according to a press release.

The study included 73 people in their 30s, 40s and 50s who have the mutation, which causes an overproduction of amyloid in the brain.

PARKINSON’S CASES COULD DOUBLE GLOBALLY BY 2050, STUDY REVEALS

Amyloid, a protein that builds up in the brain and can interfere with cognitive function, is one of the hallmarks of Alzheimer’s. 

Advertisement

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease. (iStock)

All participants had no (or very mild) cognitive decline, had a family history of Alzheimer’s, and were within 15 years before to 10 years after their expected age of developing symptoms, the release stated.

For 22 of the participants who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half — from 100% to 50% — the researchers reported.

“What we do know is that it’s possible to at least delay the onset of the symptoms of Alzheimer’s disease and give people more years of healthy life.”

“There was no effect seen in those only treated for two to three years of treatment,” senior author Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, told Fox News Digital.

Advertisement

The findings were published in the journal The Lancet Neurology on March 19.

For 22 of the participants who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half — from 100% to 50% — the researchers reported. (iStock)

Gantenerumab, a monoclonal antibody designed to target and remove amyloid plaques in the brain, was in development by Roche in Switzerland and its U.S. affiliate, Genentech.

Development was stopped in 2023, however, after Roche/Genentech’s own clinical trials found that the drug did not meet their “primary endpoint” for slowing cognitive decline in people with early symptomatic Alzheimer’s disease, according to the release.

HIGHER DEMENTIA RISK SEEN IN WOMEN WITH COMMON HEALTH ISSUE

Advertisement

“Everyone in this study was destined to develop Alzheimer’s disease and some of them haven’t yet,” said Bateman in the release.  

“We don’t yet know how long they will remain symptom-free – maybe a few years or maybe decades. In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all,” he went on.

The hope is that if late-onset Alzheimer’s trials have similar results, prevention methods could ultimately be available to the general population, according to the researchers. (iStock)

“What we do know is that it’s possible to at least delay the onset of the symptoms of Alzheimer’s disease and give people more years of healthy life.”

The hope is that if late-onset Alzheimer’s trials have similar results, prevention methods could ultimately be available to the general population, according to Bateman.

Advertisement

DEMENTIA RISK COULD INCREASE WITH LOW LEVELS OF ESSENTIAL VITAMIN

“I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk of Alzheimer’s disease,” he said. “One day soon, we may be delaying the onset of Alzheimer’s disease for millions.”

Howard Fillit, MD, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation in New York, noted that the study shows for the first time that early treatment to clear the plaques before symptoms arise can delay the onset of Alzheimer’s — “similar to how we treat and prevent other chronic diseases.”

Although gantenerumab is no longer being developed, researchers are evaluating other anti-amyloid drugs — such as remternetug, which is made by Eli Lilly — to determine whether they may prevent Alzheimer’s disease. (iStock)

“We’ve entered into a new era of Alzheimer’s research where we can not only modify the course of the disease, but where prevention is possible with therapeutic intervention,” Fillit, who was not involved in the study, told Fox News Digital.

Advertisement

Potential limitations and risks

There were several main limitations to the research, Bateman told Fox News Digital.

The number of people was limited due to the rarity of Alzheimer’s disease caused by mutations, the use of external controls, and the fact that the study started with lower doses, he said.

TWO ALZHEIMER’S DRUGS HELP PATIENTS LIVE INDEPENDENTLY AT HOME FOR LONGER PERIODS

“Many of the participants are still cognitively normal and near or past their expected age of onset even after more than eight years of treatment, so the effects could be larger or smaller with continued treatment and follow-up,” Bateman noted.

The researchers noted that anti-amyloid medications like gantenerumab have been shown to cause amyloid-related imaging abnormalities (ARIA).

Advertisement

Amyloid, a protein that builds up in the brain and can interfere with cognitive function, is one of the hallmarks of Alzheimer’s.  (iStock)

These appear on brain scans as “tiny spots of blood in the brain or localized swelling of the brain,” the release stated. 

The majority of these side effects do not cause symptoms and resolve without treatment, but in rare cases ARIA can cause serious medical issues or can even be fatal.

This most recent study showed that 30% of participants experienced ARIA, likely due to the higher doses of the drug. 

Although two participants had to stop using gantenerumab due to severe ARIA, there were no “life-threatening adverse events and no deaths,” the researchers noted. 

Advertisement

“Overall, the safety profile of gantenerumab in the extension was similar to that in the original trial and in other clinical trials of gantenerumab,” they stated.

More research needed, experts agree

Dr. Chris Vercammen, a board-certified internal medicine physician who specializes in geriatrics and palliative care, said that while these initial findings are “encouraging,” more research is needed on the effects of these medications.

“Large, randomized trials, including diverse populations and individuals with late-onset Alzheimer’s, are needed to validate these early results and determine the full potential of these treatments,” Vercammen, who is also medical director at Remo Health in California, told Fox News Digital. (He was not involved in the new study.)

   

“It’s important to note that this study’s design focused on high-risk individuals in the pre-clinical stage, and therefore does not provide sufficient data on the impact of these medications on later-stage Alzheimer’s.”

Advertisement

Fillit added that this new research opens the door for further exploration of treating preclinical Alzheimer’s.

Anti-amyloid medications like gantenerumab have been shown to cause amyloid-related imaging abnormalities (ARIA), which appear on brain scans as “tiny spots of blood in the brain or localized swelling of the brain.” (iStock)

“We look forward to seeing the longitudinal data as well as further studies around this approach,” he told Fox News Digital.

“These efforts bring us one step closer to our ultimate goal of preventing the disease before it begins.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

Although gantenerumab is no longer being developed, researchers are evaluating other anti-amyloid drugs — such as remternetug, which is made by Eli Lilly — to determine whether they may prevent Alzheimer’s disease.

“These efforts bring us one step closer to our ultimate goal of preventing the disease before it begins.”

“These rare families with mutations may wish to participate in ongoing trials,” Bateman told Fox News Digital.  

“The older general population might be interested to know that there are ongoing trials in people with amyloid plaques to test this approach to determine if Alzheimer’s symptoms could be prevented.”

For more Health articles, visit www.foxnews.com/health

Advertisement

The study was funded primarily by the Alzheimer’s Association, GHR Foundation and the National Institutes of Health (NIH).

Fox News Digital reached out to Roche/Genentech for comment.

Advertisement

Health

Katie Couric couldn’t remember the year or the president during frightening brain episode

Published

on

Katie Couric couldn’t remember the year or the president during frightening brain episode

NEWYou can now listen to Fox News articles!

Journalist Katie Couric is sharing a scary medical episode that she experienced on June 27.

In a post on Substack titled “The Day I’ll Never Remember,” she detailed a sudden episode that left her unable to recall the current month, year and president.

“I thought it was 2024. And I believed Joe Biden was president,” she wrote.

ONE WALKING HABIT COULD SIGNAL A HEALTHIER BRAIN AFTER 80, SCIENTISTS SAY

Advertisement

The event occurred while Couric was attending the Aspen Ideas Festival in Colorado, during which she participated in two public panels — one on AI and one on journalism — both of which she cannot remember at all.

“I have no idea what we talked about, or of what occurred when the panels ended,” she said.

Journalist Katie Couric is sharing a scary medical episode that she experienced on June 27. (Getty Images)

John Molner — Couric’s husband, who was in attendance at the festival and the two panels — also shared his account.

After the event, someone told Molner that Katie wasn’t feeling well. When he reached her, an EMT and a doctor were tending to her. “I could tell something was off,” he wrote. “It could have been altitude sickness, but Katie was definitely not all there.”

Advertisement

WOMAN WITH ADVANCED ALZHEIMER’S REGAINED SPEECH AND MEMORIES AFTER TAKING MAGIC MUSHROOMS

At the hospital, when Couric struggled to recall the year, the president and her grandchildren’s names, doctors began checking for a stroke.

An MRI revealed no signs of stroke, which was a relief, but “Katie’s ‘fog’ became a lot more apparent,” Molner wrote.

John Molner, Couric’s husband, who was in attendance at the festival and the two panels, also shared his account. (Getty Images)

“She repeatedly asked me the same questions: ‘What was I doing before we got to the hospital?’ ‘Why am I at the hospital?’”

Advertisement

Couric was ultimately diagnosed with transient global amnesia, a sudden, temporary episode of memory loss that prevents a person from forming new memories and may also erase some recent memories, according to Mayo Clinic.

“The cause seems to be as mysterious as the brain itself.”

It is not caused by a stroke, seizure or head injury, and it usually resolves completely within 24 hours.

“[It’s] just a very weird neural episode that’s pretty uncommon and, at least in most cases, is a ‘one and done’ experience,” Molner said.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

Couric said she finally began feeling “like herself” again around 9 p.m. and went to sleep at 2 a.m.

As TGA leaves a “permanent gap in memory” for the duration of the episode and for hours beforehand, Couric said that from around noon on that day until at least 7 p.m. will remain a “big, black hole.”

As TGA leaves a “permanent gap in memory” for the duration of the episode and for hours beforehand, Couric said that from around noon on that day until at least 7 p.m. will remain a “big, black hole.” (Getty Images)

Data shows that approximately three to eight people per 100,000 will have an episode of transient global amnesia, with people 50 years of age and older at higher risk.

The specific cause of TGA is not known, but some experts believe it stems from a “temporary dysfunction in the brain’s hippocampus — the area responsible for creating new memories,” Couric shared.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Doctors believe this is driven by brief interruptions in blood or oxygen flow, or microscopic spasm in the blood vessels.”

Episodes could potentially be triggered by intense physical exertion, emotional distress, extreme temperature changes or migraines, experts say.

CLICK HERE FOR MORE HEALTH STORIES

Approximately 15% of patients will have a recurrence 10 years later.

Advertisement

“Why did this happen to me? Was the altitude an issue? Was I dehydrated? Tired? Stressed? The literature doesn’t seem to indicate that these are contributing factors, but the cause seems to be as mysterious as the brain itself,” Couric wrote.

Anyone who experiences sudden memory loss, confusion, difficulty speaking, weakness, numbness, vision changes, severe headache or other stroke-like symptoms should seek immediate medical attention or call 911, doctors advise. (iStock)

“All I know is that those hours will be forever lost. Someone described it as my brain failing to hit the ‘record button.’”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“While this was a freaky occurrence, it could have been much more serious. So ultimately, I’m relieved — even though several hours of a Saturday in June will always be missing for me.”

Advertisement

Anyone who experiences sudden memory loss, confusion, difficulty speaking, weakness, numbness, vision changes, severe headache or other stroke-like symptoms should seek immediate medical attention or call 911, doctors advise.

Continue Reading

Health

One walking habit could signal a healthier brain after 80, scientists say

Published

on

One walking habit could signal a healthier brain after 80, scientists say

NEWYou can now listen to Fox News articles!

Older adults identified as “super movers” are about half as likely to develop cognitive impairment than their peers.

That’s according to a recent study led by Stony Brook Medicine in New York, which evaluated the cognitive function of 4,000 adults 80 and over who participated in multiple aging and longevity studies over several years.

Among this group, 6% to 10% were classified as super movers, which means they walk at a much faster pace than others of the same age and gender — at speeds comparable to people three decades younger.

COMMON VITAMIN MAY INFLUENCE BRAIN AGING IN WAYS SCIENTISTS DIDN’T EXPECT

Advertisement

The super movers were found to have about half the risk of cognitive decline compared to seniors with typical gait speed.

The findings were published in the journal Neurology on June 16.

Older adults identified as “super movers” are about half as likely to develop cognitive impairment than their peers. (iStock)

“The study reinforces that mobility and brain health are closely connected,” lead study author Dr. Joe Verghese, MD, neurologist at Stony Brook Medicine, told Fox News Digital. “This suggests that preserving mobility may be an important marker of healthy brain aging and resilience.”

‘LONGEVITY GENE’ MAY PROTECT THE BRAIN FROM ALZHEIMER’S BY BOOSTING DNA REPAIR, STUDY FINDS

Advertisement

The most intriguing finding, according to Verghese, was that super movers maintained cognitive function despite having similar dementia-related brain changes as their peers.

In postmortem brain analysis, there was no difference in dementia-related pathologies between the super movers and the slower walkers, the study stated.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“This suggests they may possess resilience mechanisms that help preserve brain function even in the presence of age-related changes,” he said. “Understanding these resilience factors could lead to new strategies for promoting healthy brain aging.”

As the study was observational, there were some limitations, and it does not prove that walking faster prevents dementia, the researchers noted.

Advertisement

Super movers were found to have about half the risk of cognitive decline compared to seniors with typical gait speed. (iStock)

“Other factors, such as cardiovascular health, physical fitness or genetics, may also contribute to both faster walking and better cognitive outcomes,” Verghese said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

This study adds to growing evidence that what’s good for the heart and muscles also benefits the brain, he noted, adding that “staying physically active remains one of the most effective, evidence-based ways to support healthy aging.”

“Walking speed is best viewed as a marker of overall health, not a treatment.”

Advertisement

“The broader message is that physical activity is important at any age,” Verghese said. “Walking is an easy step-up point because you don’t need any special equipment. You can do it inside or outdoors, and you can do it on a regular basis. You can walk with a dog, you can walk with a friend.”

Any activity is beneficial if it’s done regularly and with the right intensity, he added.

CLICK HERE FOR MORE HEALTH STORIES

Rather than just trying to walk faster, the neurologist recommends that seniors focus on maintaining mobility through regular physical activity, strength training, balance exercises and good cardiovascular health.

“Walking speed is best viewed as a marker of overall health, not a treatment,” Verghese noted.

Advertisement

Major public health guidelines from the CDC and U.S. Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity each week, such as brisk walking.

Major public health guidelines from the CDC and U.S. Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity each week, such as brisk walking. (iStock)

This can be achieved by walking 30 minutes a day, five days a week, or about 20 to 25 minutes most days. Another option is to engage in shorter sessions that add up over the day.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“You have to do it within your health limitations and medical conditions,” Verghese advised. “So if there are any medical concerns, I would get your physician to clear you before starting exercise.” The good thing about walking, he added, is that you can start at a slow pace and then gradually build up to a brisker pace.

Advertisement

“And then adding on strength and balance training, whatever age you are, I think is also important.”

Continue Reading

Health

I Tried the Viral Gelatin Weight-Loss Recipe—Here’s My Honest Take

Published

on

I Tried the Viral Gelatin Weight-Loss Recipe—Here’s My Honest Take


Advertisement





I Tried the Viral Gelatin Weight-Loss Recipe: Does It Really Work?




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading
Advertisement

Trending